Home
About
Overview
Sharing Data
ORCID
Help
History (7)
Management of Sepsis and Septic Shock
Respiratory guidelines--which real world?
University of Chicago phase II consortium trial of selumetinib (MEKi) demonstrates low tolerability and efficacy in relapsed DLBCL.
Risk of Procedural Hemorrhage.
Phase II study of yttrium-90-ibritumomab tiuxetan in patients with relapsed or refractory mantle cell lymphoma.
See All 7 Pages
Find People
Find Everything
Edit My Profile
My Person List (
0
)
Return to Top
Login
Username
Password